Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
in Copenhagen, showing improved intracranial progression-free survival in EGFR-mutated non-small cell lung cancer and confirming that a Biologics License Application has been submitted to the FDA. The breadth of the ivonescimab program, spanning 15 Phase III studies across lung and colorectal cancer and involving global and China-based trials with partner Akeso, underscores how central this single asset has become to Summit's pipeline. With ivonescimab's Phase III data and FDA filing now in focus, we'll explore how this potential first-in-class therapy shapes Summit's investment narrative. Uncover the next big thing with 30 elite penny stocks that balance risk and reward. What Is Summit Therapeutics' Investment Narrative? To own Summit today, you have to believe ivonescimab can transition from a single drug to a durable oncology franchise, despite heavy cash burn and zero product revenue so far. The ELCC data and confirmation of the FDA filing sharpen the near term catalyst
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]Yahoo! Finance
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Business Wire
- Akeso Reports Full-Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics (SMMT) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 2/23/26 - Beat
SMMT
Sec Filings
- 2/23/26 - Form S-8
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- SMMT's page on the SEC website